NASDAQ:CBIO • KYG2545C1042
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CRESCENT BIOPHARMA INC (CBIO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-21 | Guggenheim | Initiate | Buy |
| 2025-08-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-25 | Jefferies | Initiate | Buy |
| 2025-08-11 | HC Wainwright & Co. | Initiate | Buy |
| 2025-07-14 | Wedbush | Initiate | Outperform |
| 2025-06-25 | Stifel | Initiate | Buy |
| 2025-06-18 | LifeSci Capital | Initiate | Outperform |
| 2021-11-15 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2021-08-06 | Raymond James | Maintains | Outperform |
| 2021-04-29 | Raymond James | Maintains | Outperform |
| 2021-02-10 | Piper Sandler | Initiate | Overweight |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.16M -88.58% | 80K -93.10% | 10K -87.50% | -100.00% | 3.825M | 5.1M 33.33% | 34.578M 578.00% | 104.99M 203.63% | 290.33M 176.53% | 627.86M 116.26% | 1.226B 95.27% | |||
| EBITDA YoY % growth | -63.19M -23.32% | -47.19M 25.32% | -39.122M 17.10% | N/A 16.99% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -63.45M -23.18% | -47.4M 25.30% | -39.275M 17.14% | -33.887M 17.23% | -95.535M -193.87% | -121.36M -27.03% | -148.388M -22.27% | -177.287M -19.48% | -238.154M -34.33% | -239.01M -0.36% | -82.2M 65.61% | 140.82M 271.31% | 445.48M 216.35% | |
| Operating Margin | -5,469.83% | -59,250.00% | -392,753.00% | N/A | N/A | N/A | -3,879.44% | -3,476.22% | -688.74% | -227.65% | -28.31% | 22.43% | 36.34% | |
| EPS YoY % growth | -123.00 -10.81% | -88.00 28.46% | -58.00 34.09% | -0.62 98.93% | -12.58 -1,633.24% | -4.24 60.54% | -3.85 9.18% | -4.41 -14.61% | -4.62 -4.66% | -4.03 12.81% | -3.68 8.53% | 0.61 116.48% | 10.08 1,560.50% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.93 76.81% | -1.08 78.18% | -1.50 -17.80% | -1.50 -177.16% |
| Revenue Q2Q % growth | -100.00% | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -28.559M -1,090.49% | -115.343M -448.47% | -23.486M 5.61% | -23.996M 27.04% |
All data in USD
15 analysts have analysed CBIO and the average price target is 29.92 USD. This implies a price increase of 189.36% is expected in the next year compared to the current price of 10.34.
The consensus EPS estimate for the next earnings of CRESCENT BIOPHARMA INC (CBIO) is -0.93 USD and the consensus revenue estimate is 0 USD.
The consensus rating for CRESCENT BIOPHARMA INC (CBIO) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.